Raphaelle Despreaux1, Salomon Y Cohen2,3, Oudy Semoun1, Olivia Zambrowski1, Camille Jung4, Hassiba Oubraham1, Eric H Souied1,4. 1. Department of Ophthalmology, Hôpital Intercommunal de Créteil, Faculté de médecine Henri Mondor, Université Paris Est Créteil, 40 avenue de Verdun, 94000, Créteil, France. 2. Department of Ophthalmology, Hôpital Intercommunal de Créteil, Faculté de médecine Henri Mondor, Université Paris Est Créteil, 40 avenue de Verdun, 94000, Créteil, France. sycsyc75@gmail.com. 3. Centre Ophtalmologique d'Imagerie et de Laser, Paris, France. sycsyc75@gmail.com. 4. Centre de Recherche Clinique- Centre de Ressources Biologiques, Hôpital Intercommunal de Créteil, Faculté de médecine Henri Mondor, Université Paris Est Créteil, Créteil, France.
Abstract
PURPOSE: This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) who had previously switched from ranibizumab to aflibercept. METHODS: This retrospective double-center study included 45 patients with nAMD who were previously treated with ranibizumab, then aflibercept, and then ranibizumab again, regardless of the number of intravitreal injections received. The primary outcome was change in best-corrected visual acuity (BCVA) measured on the Early Treatment Diabetic Retinopathy Study ETDRS chart before (T0) and after (T1) the switch, and 3 months after the switchback (T2). Secondary outcomes included changes in central foveal thickness (CFT) measured at T0, T1, and T2, as analyzed on spectral-domain optical coherence tomography (SD-OCT), and the percentage of patients gaining five letters or better. RESULTS: Forty-seven eyes of 45 patients were switched back from aflibercept to ranibizumab. The mean BCVA was 67.4 ± 13.4 at T0, 66.7 ± 14.4 at T1, and 68.2 ± 13.9 at T2. BCVA was significantly improved between T1 and T2 (p = 0.0230), but not between T0 and T1 (p = 0.5153) or between T0 and T2 (p = 0.4248). The mean CFT decreased from 317.8 μm ± 89.6 at T0 to 306.9 μm ±68.0 at T1, and to 291.2 μm ± 76.6 at T2. The decrease in CFT was not statistically significant between either T0 and T1 or T1 and T2, but was significant between T0 and T2, when compared before switch and after switchback (p = 0.0027). However, when considering eyes that received three or more consecutive intravitreal injections of aflibercept before switchback, the statistical significance between T1 and T2 was lost, although a trend towards significance remained (p = 0.06). Thirteen eyes (27.7 %) gained five letters or more (range, 5-15 letters) after switchback. CONCLUSIONS: A short-term benefit of switchback from one anti-VEGF agent to another was observed in patients with nAMD who had shown no benefit from the initial switch.
PURPOSE: This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) who had previously switched from ranibizumab to aflibercept. METHODS: This retrospective double-center study included 45 patients with nAMD who were previously treated with ranibizumab, then aflibercept, and then ranibizumab again, regardless of the number of intravitreal injections received. The primary outcome was change in best-corrected visual acuity (BCVA) measured on the Early Treatment Diabetic Retinopathy Study ETDRS chart before (T0) and after (T1) the switch, and 3 months after the switchback (T2). Secondary outcomes included changes in central foveal thickness (CFT) measured at T0, T1, and T2, as analyzed on spectral-domain optical coherence tomography (SD-OCT), and the percentage of patients gaining five letters or better. RESULTS: Forty-seven eyes of 45 patients were switched back from aflibercept to ranibizumab. The mean BCVA was 67.4 ± 13.4 at T0, 66.7 ± 14.4 at T1, and 68.2 ± 13.9 at T2. BCVA was significantly improved between T1 and T2 (p = 0.0230), but not between T0 and T1 (p = 0.5153) or between T0 and T2 (p = 0.4248). The mean CFT decreased from 317.8 μm ± 89.6 at T0 to 306.9 μm ±68.0 at T1, and to 291.2 μm ± 76.6 at T2. The decrease in CFT was not statistically significant between either T0 and T1 or T1 and T2, but was significant between T0 and T2, when compared before switch and after switchback (p = 0.0027). However, when considering eyes that received three or more consecutive intravitreal injections of aflibercept before switchback, the statistical significance between T1 and T2 was lost, although a trend towards significance remained (p = 0.06). Thirteen eyes (27.7 %) gained five letters or more (range, 5-15 letters) after switchback. CONCLUSIONS: A short-term benefit of switchback from one anti-VEGF agent to another was observed in patients with nAMD who had shown no benefit from the initial switch.
Authors: James A Eadie; Justin L Gottlieb; Michael S Ip; Barbara A Blodi; Ronald P Danis; Suresh R Chandra; T Michael Nork; Michael M Altaweel; Brendan S Stern-Hogan Journal: Ophthalmic Surg Lasers Imaging Retina Date: 2014 Sep-Oct Impact factor: 1.300
Authors: Wyatt B Messenger; J Peter Campbell; Ambar Faridi; Loton Shippey; Steven T Bailey; Andreas K Lauer; Christina J Flaxel; Thomas S Hwang Journal: Br J Ophthalmol Date: 2014-05-02 Impact factor: 4.638
Authors: Benjamin Bakall; James C Folk; H Culver Boldt; Elliott H Sohn; Edwin M Stone; Stephen R Russell; Vinit B Mahajan Journal: Am J Ophthalmol Date: 2013-05-22 Impact factor: 5.258
Authors: Magda Gharbiya; Ludovico Iannetti; Francesco Parisi; Umberto De Vico; Maria Laura Mungo; Marco Marenco Journal: Biomed Res Int Date: 2014-05-07 Impact factor: 3.411
Authors: Rehan M Hussain; Andrea Neal; Nicolas A Yannuzzi; Kevin H Patel; Siya Huo; Seenu M Hariprasad; Sumit P Bhatia Journal: Ther Adv Ophthalmol Date: 2021-12-13
Authors: Richard P Gale; Ian Pearce; Nicole Eter; Faruque Ghanchi; Frank G Holz; Steffen Schmitz-Valckenberg; Konstantinos Balaskas; Ben J L Burton; Susan M Downes; Haralabos Eleftheriadis; Sheena George; David Gilmour; Robin Hamilton; Andrew J Lotery; Nishal Patel; Priya Prakash; Cynthia Santiago; Saju Thomas; Deepali Varma; Gavin Walters; Michael Williams; Armin Wolf; Rosina H Zakri; Franklin Igwe; Filis Ayan Journal: Br J Ophthalmol Date: 2019-08-05 Impact factor: 4.638